Objective To observe the effect of Naoxueshu oral liquid on cerebral infarction and its effect on hemorheology, homocysteine and vascular endothelial growth factor (VEGF). Methods from February 2017 to February 2018, 70 cases of cerebral infarction patients admitted to Tangjiazhuang Hospital, Kailuan, Hebei Province were selected and divided into observation group and control group by random number table method, with 35 cases in each group. Patients in both groups were given symptomatic treatment such as anticoagulation, anti-platelet aggregation, dehydration, reducing intracranial pressure, and scavenging oxygen free radicals, etc, and the observation group was given cerebrohemohy Naoxueshu therapy on this basis. The therapeutic effect, NIHSS, mRS score, hemorheology, Hcy and hs-CRP were compared between the two groups. Results After treatment, the NIHSS and mRS scores of patients in the two groups were lower than those before treatment, and the differences were statistically significant (P ＜ 0.05), the NIHSS and mRS scores of the observation group were lower than those of the control group, and the differences were statistically significant (P ＜ 0.05). Hcy and hs-CRP in the two groups decreased compared with that before treatment, and the differences were statistically significant (P ＜ 0.05). Hcy, hs-CRP and VEGF levels in the observation group were lower than those in the control group, with statistically significant differences (P ＜ 0.05), fibrinogen, plasma viscosity, low whole blood viscosity, medium whole blood viscosity and high whole blood viscosity of the two groups were all lower than before treatment, and the differences were statistically significant (P ＜ 0.05), the indexes of hemorheology in the observation group were lower than those in the control group, and the differences were statistically significant (P ＜ 0.05). The total effective rate in the observation group was higher than that in the control group, and the difference was statistically significant (P ＜ 0.05). Conclusion The treatment of cerebral infarction patients with cerebral blood thinning oral liquid is helpful to improve blood coagulation function, promote nerve function repair, and improve the quality of life of patients.%目的 观察脑血疏口服液治疗脑梗死的效果及对患者血液流变学、同型半胱氨酸及血管内皮生长因子(VEGF)的影响.方法 选取河北省开滦唐家庄医院2017年2月～2018年2月收治的脑梗死患者70例,采用随机数字表法将其分为观察组和对照组,每组各35例.两组患者均给予抗凝、抗血小板聚集、脱水降颅压、清除氧自由基等对症治疗,观察组在此基础上给予脑血疏治疗.观察比较两组患者治疗效果、神经功能缺损评价量表(NIHSS)、残疾程度量表(mRS)评分、血液流变学、同型半胱氨酸(Hcy)、超敏C反应蛋白(hs-CRP)等相关指标的变化.结果 治疗后,两组患者NIHSS、mRS评分较治疗前降低,差异有统计学意义(P ＜ 0.05).观察组NIHSS、mRS评分低于对照组,差异有统计学意义(P ＜ 0.05).两组患者Hcy、hs-CRP 较治疗前均有所下降,差异有统计学意义(P ＜ 0.05);观察组患者Hcy、hs-CRP、VEGF水平低于对照组,差异有统计学意义(P ＜ 0.05).两组纤维蛋白原、血浆黏度、低切全血黏度、中切全血黏度及高切全血黏度均低于治疗前,差异有统计学意义(P ＜ 0.05).观察组血液流变学各指标低于对照组,差异有统计学意义(P ＜ 0.05).观察组治疗总有效率高于对照组,差异有统计学意义(P ＜ 0.05).结论 对脑梗死患者给予脑血疏口服液治疗,有助于改善凝血功能,促进神经功能修复,改善患者生存质量.
展开▼
